Sanofi US News

Provention is currently developing PRV-101 as a vaccine for acute coxsackie infection and to potentially prevent the onset of T1D

* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL

Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m., ET

* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)

- Top-line data from the "PULSE" clinical trial expected in the second quarter of 2019

-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype

- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery

* Libtayo is the third anti-PD-1 approved in the U.S.

* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy

Industry executive adds considerable financial expertise as audit committee chairperson

- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder

- Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention

Nearly 70 million doses to be manufactured this season

- Company invests €66 million in Chengdu, Sichuan province, China

- Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin

-- Patients treated with cemiplimab experienced robust anti-tumor effects

* In steroid-sparing VENTURE trial, Dupixent-treated patients substantially reduced use of oral corticosteroids, yet had fewer exacerbations and improved lung function compared to placebo.

* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018

-- Agreement provides Praluent at lower net price and enables streamlined patient access based on physician attestation

- If approved, health care professionals will be able to use the same 0.5 mL dose of Fluzone Quadrivalent vaccine with all patients ages 6 months and older for whom flu vaccination is recommended - which may provide more flexibility and convenience to immunizers.

* Max SoloStar holds more insulin than any other long-acting insulin pen

- Sanofi teams up with television personality Adam Savage and allergist Dr. Neeta Ogden to help dispel common allergy misconceptions with facts

* Precision medicine approach will focus efforts on high-risk patients, such as those who have had heart attacks or unstable angina and cannot reduce their LDL-C below 100 mg/dL despite maximally-tolerated statins

* ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who added Praluent® (alirocumab) Injection to maximally-tolerated statins experienced significantly fewer major adverse cardiovascular events compared to those on maximally-tolerated statins alone

Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma

High and durable response rate in disease without any FDA-approved therapies

* First FDA-approved follow-on mealtime insulin

Phase 3 trials will evaluate isatuximab, an anti-CD38 antibody, in combination with other cancer treatments 

First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec

Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec